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Abstract 
The management of chemotherapy-induced nausea and vomiting (CINV) remains an issue in the 
treatment of colorectal cancer using oxaliplatin based regimens. Certain traditional plant-based 
medicines (TMs) have histories of use for nausea and vomiting and have integrated with conventional 
therapies for CINV. To assess the effectiveness of integrative management of CINV, meta-analysis 
was conducted of 27 randomised controlled studies (1,843 participants) published from 2005 to 2013. 
The oxaliplatin plus TM groups showed significantly reduced CINV (RR 0.65 [0.59, 0.71], I²=28%) 
compared to oxaliplatin controls, with or without the addition of conventional anti-emetics. Further 
sensitivity analyses based on the ingredients of the TMs identified six plants (Atractylodes 
macrocephala, Poria cocos, Coix lacryma-jobi, Astragalus membranaceus, Glycyrrhiza uralensis, 
Panax ginseng) that were associated with significant reductions in CINV without important 
heterogeneity. Experimental studies of these six plants have reported inhibitory effects on nausea and 
vomiting (or its animal equivalent), regulation of gastrointestinal motility, gastro-protective effects, 
and antioxidant actions which may at least partially explain the effects identified in the meta-analyses 
of the clinical trial results. These plants warrant further clinical research as additions to chemotherapy 
regimens in patients whose CINV is not sufficiently well-controlled by conventional therapies. 
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Abbreviations 
5-FU: 5-Fluorouracil 
AEs: Adverse Events  
CINV: Chemotherapy-induced Nausea and Vomiting 
CNKI: China Academic Journals 
CQVIP: Chinese Science and Technology Journals  
CRC: Colorectal Cancer 
FOLFOX: 5-Fluorouracil (5-FU) plus Leucovorin (LV) combined with Oxaliplatin 
G-CSF: Granulocyte colony-stimulating factor  
KPS: Karnofsky Performance Status 
LV: Leucovorin 
NCI-CTC: National Cancer Institute Common Toxicity Criteria 
RCT: Randomized Controlled Trial 
RD: Risk Difference 
RR: Risk Ratio 
TMs: Traditional Medicines  
WHO: World Health Organisation 
 
Page 3 of 23
http://mc.manuscriptcentral.com/ptr
Phytotherapy Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Introduction 
 
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event in cancer treatment. 
Risk factors for CINV following chemotherapy include type of chemotherapeutic drug, patient’s age 
less than 50, female, history of low prior chronic alcohol intake, and history of previous 
chemotherapy-induced emesis. Over seventy percent of patients receiving oxaliplatin regimens 
experience CINV (Navari, 2009). CINV tends to get worse as the number of treatment cycles 
increases. This significantly reduces the quality of life of patients, can result in poor compliance with 
their chemotherapy schedule and can lead to deterioration of physical and mental status (Lohr, 2008). 
 
The mechanisms of CINV are complex. CINV can be initiated by enterochomaffin cells in the 
gastrointestinal tract releasing serotonin (5-HT) in response to damage of gastrointestinal epithelium 
and activation of the chemoreceptor trigger zone which detects potential toxins. Activation of vagal 
afferent fibres stimulates the vomiting center in the medulla, which in turn sends impulses via efferent 
fibres to activate the vomiting response. Antiemetic drugs act by blocking neuronal pathways 
involved at various stages in the emetic response, mainly via antagonism of 5-hydroxytryptamine (5-
HT3) receptors, dopamine receptors, neurokinin-1(NK-1) and/or acetylcholine, corticosteroid, 
histamine, cannabinoid, and/or opiate receptors (Lohr, 2008; Navari, 2009).  
 
Oxaliplatin regimens used in colorectal cancer (CRC) are considered to have moderate emetic risk 
and the preventative use of 5-HT3 antagonists combined with dexamethasone is recommended, with 
the additional use of NK-1 antagonists in selected patients (NCCN, 2012). Despite the introduction of 
these effective anti-emetic agents, CINV remains a significant issue for people undergoing 
chemotherapy (Navari, 2009). 
 
A number of traditional medicines (TMs) have been used to alleviate nausea and vomiting. Ginger 
(Zingiber officinale Roscoe) has been used for nausea in a number of countries and evidence from 
animal studies suggests anti-CINV effects (Handiadka et al., 2012a). However, a systematic review of 
seven randomised controlled trials (RCTs) of ginger in CINV management in various cancers found 
inconsistent results between studies (Marx et al., 2013). Other plants that have been reported to 
alleviate CINV in animal models include Panax ginseng C. A. Mey., Panax quinquefolius L., Panax 
notoginseng (Burk.)F. H. Chen, Scutellaria baicalensis Georgi, Ganoderma lucidum (Fr.)Karst., Mint 
oil (Mentha spp) and grape seed extract (Handiadka et al., 2012b). A number of possible mechanisms 
for the reported anti-CINV actions of these plants have been proposed. These include inhibition of 5-
HT3 receptor, substance P and NK1 receptors, antioxidant and free radical scavenging activity, anti-
inflammatory actions, chemo and radio-protective effects, immunomodulation, neuromodulation, 
antispasmodic effects, and regulation of gastrointestinal motility.Since these TMs may contain 
multiple bioactive compounds it appears likely that multiple mechanisms are involved (Handiadka et 
al., 2012b, Suzuki et al., 2013).  
 
Previous reviews have reported that multi-ingredient TMs combined with chemotherapy could reduce 
CINV in various cancers (Dong et al., 2010; Li and Ling, 2012; Ohnishi and Takeda, 2015; Liu et al., 
2008). In advanced CRC, a meta-analysis of RCT results showed FOLFOX4 combined with TMs 
produced a 10.3% reduction in grade 3/4 nausea and vomiting compared to FOLFOX4 alone (Chen et 
al., 2014). However, numerous TMs were used in these studies so it remains unclear whether any 
particular plant ingredients were responsible for the reported effects.  
 
The aims of this review and meta-analysis are to assess whether integrative management of CRC, in 
which TMs are added to oxaliplatin regimens, reduced the incidence of CINV and whether any 
particular TMs showed promise for further research into their anti-emetic and/or nausea alleviating 
effects. 
 
Method 
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PubMed, EMBASE, Cochrane CENTRAL, CINAHL, Science Direct, PsycINFO, China Academic 
Journals (CNKI) and Chinese Science and Technology Journals (CQVIP) were searched from their 
respective inceptions for RCTs that combined an oxaliplatin regimen with TM for the treatment of 
participants who had been diagnosed with CRC based on pathology tests and measured CINV as an 
outcome. There was no restriction on participant age or gender, inpatient or outpatient, or route of 
administration of the TM, or concurrent use of anti-emetic drugs.The terms used for PubMed and a 
list of journals that were hand-searched are provided in Supp 1. 
Review methods were based on Cochrane Handbook 5.1.0 (Higgins and Green, 2011). Data were 
extracted independently by MC & IZ who also assessed Risk of Bias,with mediation by AZ or BM. 
Meta-analysis was conducted using Review Manager (RevMan) 5.1 as Risk Ratio (RR) with 95% 
confidence interval (95% CI) fixed effect model. Heterogeneity was measured using I². Risk 
difference (RD) was used as a measure of absolute difference. Publication bias was assessed using a 
funnel plot (Higgins and Green, 2011). Studies with zero events were included to avoid 
overestimation of effect (Fiedrich et al., 2007). The following subgroup and sensitivity analyses were 
planned: 1. route of TM administration; and 2.composition of the multi-ingredient orally administered 
TMs.  
The approach to analyzing the subgroups of TM interventions that contained the same ingredients 
(mainly plants) was based on the method described in (Chen et al., 2015). The rationale for this 
approach was that many of the multi-ingredient TM interventions used different combinations of the 
same plants. Therefore, by investigating the pooled effects of multiple studies that employed the same 
plant, it may be possible to identify which plants contributed to the observed effects on CINV. In 
addition, it may also be possible to identify specific combinations of plants that showed the greatest 
contributions to CINV alleviation. Briefly, the approach involved a multi-level procedure. At level 1, 
all studies that employed the same plant were treated as a sub-group and the pooled RR(95%CI) and 
I2 for CINV were calculated. This was done for all plants that appeared in two or more studies. The 
results were listed in ascending order and significant results were noted. When the sub-group showed 
no significant effect on CINV and/or there was important heterogeneity in the pooled result (I
2
 greater 
than 30%), the plant was eliminated from further consideration. At level two, subgroups of studies 
that employed the same two plants in the TM interventions were identified and the RRs were 
calculated for each pool. At level three, combinations of three plants were considered and so on until 
there were no possible combinations that showed significant effects. This approach produced a matrix 
of pooled RRs for multiple sub-groups of studies.  
The following five criteria were applied to the matrix of results to identify plants and combinations of 
plants that showed promise for further research into their effects on CINV. 1. the RR of the sub-group 
of studies that employed the plant was significantly lower than the control; 2. the RR was equal or 
lower than the RR for all the orally administered multi-ingredient TM interventions; 3. no important 
heterogeneity (I2 below 30%); and 4: the RR results for the plant were significant at multiple levels of 
combination; 5. the plant was not always combined with another particular plant, therefore it was 
possible to assess the independent contribution of that plant.  
Results 
Following screening of the 2,648 citations derived from database searches and the 54 studies from 
print journal searches, 88 full-text studies were evaluated. Finally, 30 studies were included in the 
review. Three studies did not provide data suitable for pooling (Chen et al. 2005; Deng and Shen, 
2010; Liang et al., 2009), so 27 studies, published from 2005 to 2013, that enrolled 1,843 
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(T:960/C:883) assessable participants were included in the meta-analyses (Figure 1). Six studies 
employed commercially available injections and 21 studies used orally administered TMs. All studies 
used the WHO system or the National Cancer Institute Common Toxicity Criteria (NCI-CTC). These 
systems are comparable and divide nausea and vomiting into 4 grades (Miller et al., 1981; National 
Cancer Institute, 1999). Study characteristics are presented in Table 1. 
Methodological assessment 
Thirteen studies (48.1%) were judged as ‘low’ risk of bias for sequence generation (Table 1). One 
study was blinded, used a placebo control for the TM and described allocation concealment (Kono et 
al., 2013). The other studies were judged as ‘high risk’ for blinding of outcome assessment since 
nausea is a subjective outcome which is usually recorded by participants and personnel so results 
could have been influenced by lack of blinding. Two studies were judged as ‘high risk’ for incomplete 
outcome data since reasons for dropouts were not given and ‘intent to treat’ was not used (Li et al., 
2007; Zhang et al., 2010). Studies with no dropouts were judged as ‘low risk’. Studies were judged as 
‘low risk’ of selective outcome reporting when there was a published protocol and results for all 
outcome measures were reported. Studies with no protocol were judged as ‘unclear’. The Funnel Plots 
suggest risk of publication bias was low for the oral administration group (Figure Supp 1).  
Meta-analysis of reduction of nausea and vomiting 
Meta-analysis was conducted for all grades of nausea and vomiting combined. When RR is less than 
+1 and RD is less than zero (IV model, fixed, 95% CI), it favors the test group. A lower RR indicates 
a lower risk of nausea and vomiting. 
 
Total group 
For all 27 studies, the test groups showed significantly reduced nausea and vomiting (RR 0.65 [0.59, 
0.71], I²=28%)(Figure 2). The absolute risk reduction was 24% compared to controls (RD= -0.24 [-
0.28, -0.19], I²=48%). In the 17 studies that stated anti-emetic drugs, such as ondansetron or 
granisetron, were used in both groups the RR was 0.68 [0.60, 0.77], I²=32% whereas in the studies 
that did not mention use of anti-emetic drugs (n=10) the RR was 0.60 [0.51, 0.70], I²=19%. 
Injection group 
Four different injection products were tested in 6 studies (Table 1). There was a significant reduction 
in nausea and vomiting (RR 0.73 [0.61, 0.86], I²=60%, RD= -0.20 [-0.29, -0.12], I²=50%) in the TM 
plus oxaliplatin groups. The heterogeneity was moderate to substantial (Figure 2). Co-kushen 
Injection (n=2) (Ding et al., 2010; Tao and Xu, 2013) showed significantly reduced nausea and 
vomiting (RR 0.66 [0.50, 0.86], I² =64%) but there was substantial heterogeneity. Kang'ai Injection 
(n=2) (Qiu 2011; Yang, 2008) showed a significant reduction with no important heterogeneity (RR 
0.47 [0.29, 0.77], I² =28%).  
Oral administration group 
The TMs were administered orally as decoctions, capsules or tablets in 21 studies. The combination of 
TMs plus oxaliplatin showed a significant reduction in nausea and vomiting incidence compared to 
the same oxaliplatin regimens (RR 0.62 [0.55, 0.69], I²=5%). The absolute risk reduction was 25% 
(RD -0.25 [-0.30, -0.20], I²=49%)(Figure 2). 
Effects of individual plant-based ingredients in orally administered TMs 
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The orally administered TMs contained 98 different plant-based ingredients with an average of 12 
ingredients per TM intervention. The 48 plants that were used in two or more studies were included in 
the following sub-group analyses. Thirty of these plants showed significant RRs for reduction of 
incidence of CINV with low heterogeneity (I² < 30%). The effects of these plants were also assessed 
when they appeared as pairs, triplets and higher level combinations in the TM interventions. 
Significant RR results with low heterogeneity that were equal or lower than the total pool for the oral 
interventions RR 0.62 [0.55, 0.69] are reported in Table 2 and Table Supp 1. The full botanical name 
and Chinese name in pin yin of each plant is given when it is first mentioned in the text. 
Subsequently, the name is shortened to genus only.  
The following plants were the most frequently used in the TM interventions: Poria cocos (Schw) 
Wolf (fu ling)(n=16); Atractylodes macrocephala Koidz. (bai zhu) (n=16); Coix lacryma-jobi L. (yi 
ren) (n=14); Astragalus membranaceus (Fisch.) Bge. (huang qi) (n=13), and Codonopsis pilosula 
(Franch.). Nannf. (dang shen) (n=12). 
Level 1: Single plants 
Of the 30 plants included at the level 1 analysis (Table 2), most were always associated with another 
particular plant in the TM interventions so it was not possible to determine if they made an 
independent contribution to the RR result. However, the following seven plants did not always appear 
in association with another particular plant. Of these, Panax ginseng C. A. Mey. (ren shen) (n=4) had 
the lowest RR (0.51 [0.39, 0.66], I²=0%), followed by Poria (n=16) (RR 0.61 [0.54, 0.69], I²=15%), 
Coix (n=14) (RR 0.61 [0.53, 0.70], I²=29%), Codonopsis (n=12) (RR 0.61 [0.52, 0.72], I²=28%), 
Panax notoginseng (Burk.) F.H. Chen (tian qi) (n=4) (RR 0.61 [0.43, 0.87], I²=0%), Atractylodes 
(n=16) (RR 0.62 [0.54, 0.71], I²=13%), and Astragalus (n=13) (RR 0.65 [0.55, 0.76], I²=0%). 
Level 2: Pairs of plants 
Seven pairs of plants showed RRs that were lower than the total pool (Table Supp1). The lowest RRs 
were for Panax G.+Astragalus (n=4) (RR 0.49 [0.35, 0.67], I²=0%) followed by Poria+ Dioscorea 
opposita Thunb.(shan yao)(n=5)(RR 0.56 [0.47, 0.67], I²=0%). 
Level 3: Combinations of three plants 
Six different triplets showed significant RRs that were lower than the total pool. The combination of 
Dioscorea+Coix+Poria (n=3) had the lowest RR (0.49 [0.37, 0.65], I²=0%), followed by Panax G 
+Atractylodes+Coix (n=3) (RR 0.52 [0.39, 0.69], I²=0%). 
Level 4: Combinations of four plants  
Atractylodes+Poria+Coix+ Glycyrrhiza uralensis Fisch (gan cao) was the only combination that was 
significant and lower or equal to the pool (RR 0.51 [0.38, 0.70], I²=0%, n=3).  
Level 5: Combinations of five plants 
Three combinations of five plants showed RRs lower than the total pool. Astragalus+Atractylodes+ 
Coix+ Lycium barbarum L. (gou qi zi) + Scutellaria barbata D. Don. (ban zhi lian)(n=3) had the 
lowest RR (0.58 [0.41, 0.83], I²=0%).  
Level 6: Combinations of six plants 
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Six combinations of six plants showed significant RRs lower than the total pool. The lowest RR (0.50 
[0.36, 0.69], I²=0%) was for Panax G+ Dioscorea + Coix+ Glycyrrhiza+ Atractylodes+ Poria (n=2). 
Level 7: Combinations of seven plants 
One combination of seven plants was lower than the total pool: Codonopsis+ Atractylodes+ 
Astragalus+ Coix+ Poria+ Crataegus pinnatifida Bge (shan zha)+ Hordeum vulgare L. (mai ya) (n=2) 
(RR 0.47 [0.33, 0.68], I²=0%). 
TMs with consistent results at multiple levels 
Six plants showed significantly reduced RRs that were lower than or equal to the pool with low 
heterogeneity at multiple levels. Atractylodes, Poria and Coix appeared at all seven levels when used 
as components of various TM interventions. Glycyrrhiza appeared at five levels while Astragalus and 
Panax G appeared at four levels.  
Discussion 
The meta-analysis showed reduction in CINV in both the injection and oral groups but there was 
substantial heterogeneity in the injection group (I²=60%) compared to the oral group (I²=5%). In the 
oral intervention studies the absolute risk reduction was 25% which was higher than for the injection 
group (20%). In a previous meta-analysis of tumour response rate, the injection groups appeared more 
effective than the oral groups (Chen et al., 2015).One likely reason for these differences is the 
injection products are mainly aimed at aiding tumour response rather than reducing CINV. 
Nevertheless, the result for the two studies of Kang’ai injection, which is composed of Panax G, 
Astragalus and Sophora flavescens Ait., showed significant reduction in CINV incidence without 
important heterogeneity (I²=28%).  
It has been suggested that combining certain TMs with anti-emetics results in greater benefit (Dong, 
2012). In the total group, there was a slightly reduced benefit in the 17 studies that used anti-emetic 
drugs compared to the ten that did not. However, it is possible that some studies did not report the use 
of anti-emesis medications since these are in routine use. Therefore this result is difficult to interpret. 
This issue warrants further investigation. 
The following six plants appeared at multiple levels of combination in the oral interventions: 
Atractylodes (n=16), Poria (n=16), Coix (n=14), Astragalus (n=13), Glycyrrhiza (n=5), and Panax G 
(n=4). This list contains the plants with the highest overall frequencies, such as Atractylodes and Poria, 
and also some lower frequency plants such as Glycyrrhiza and Panax G. Conversely, some relatively 
frequent plants such as Curcuma (n=7) did not show an elevated RR. Therefore, the selection process 
did not simply reflect overall frequency within the data set.  
Ginger was not included in the final analyses, although it appeared to significantly reduce CINV (RR 
0.43 [0.31, 0.61]), since it was used in only two studies and the heterogeneity was substantial 
(I²=69%). A number of other plants used traditionally for nausea were also excluded for the same 
reasons. It is important to note that the plants selected above are not the only plants that showed 
improved RR for CINV when they were included in a TM intervention, what they showed was 
consistent effects in multiple studies and in multiple combinations. Another caveat on the 
interpretation of these results is that the short-listed herbs cannot be ranked in order of effectiveness 
since each RR was based on a different sub-group of studies.  
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Based on the information in the clinical trial reports it was not possible to determine whether the 
short-listed plants were included in order to reduce CINV or for other reasons. This issue is made 
more complex since plants are considered to have multiple effects in traditional medicine. However, 
all are traditionally used for treating gastrointestinal disorders including nausea, bloating, fatigue, 
poor appetite, and diarrhoea (Bensky et al., 2004).  
The effects of extracts and compounds derived from the six plants identified as potentially reducing 
CINV have received research attention in experimental models in animals and cell-lines to assess their 
effects on emesis, pica, gastrointestinal motility and gastro-protection. The volume of published 
research is variable with Ginseng, Atractylodes, and Poria having received the most attention. This 
research is reviewed for each of the six plants below. 
Panax ginseng 
The anti-emetic effect of Korean red ginseng total extract (KRGE) on nausea and vomiting was 
investigated in ferrets administered intraperitoneal cisplatin (7.5mg/kg) which induced both nausea 
and vomiting with one-hour latency. The animals were monitored very 30 mins and the total number 
of episodes of nausea and vomiting were marked. Pre-treatment with orally administered KRGE one 
hour and two hours before cisplatin significantly attenuated the cisplatin-induced nausea and vomiting 
in a dose-dependent manner. No significant effect was evident when KRGE was administered 4 hours 
prior to cisplatin (Kim et al., 2005). 
In rodents, emetics do not produce vomiting but instead induce pica - the eating of kaolin. In rats, the 
effects of an extract of Korean ginseng (KG) administered before and after cisplatin, on pica, food 
intake, body weight, haematological parameters and histopathology was investigated by 
Raghavendran et al (2011). Pre-treatment with KG one hour before cisplatin significantly reduced 
kaolin intake at 24, 48, and 72 hours post-cisplatin. Normal food intake significantly improved 
compared to the group that received cisplatin alone and there was less reduction in body weight. Post-
treatment KG showed similar effects. The increases in th  levels of white blood cells, neutrophils, 
lymphocytes induced by cisplatin were significantly lower in the rats pre-treated with KG, suggesting 
that KG reduced cisplatin-induced inflammation. Cisplatin-induced damage to the gastric mucosa and 
small intestine was reduced by pre-treatment, but not by post-treatment, with KG (Raghavendran et 
al., 2011). A similar result was obtained using American ginseng berry extract (AGBE) and 
ginsenoside Re which is one of its constituents. Pre-treatment reduced cisplatin-induced pica and 
improved food intake. When tested for antioxidant actions, both AGBE and ginsenoside Re were 
found to scavenge superoxide and hydroxyl radicals (Mehendale et al., 2005).  
Pre-treatment with ginsenoside Rg2 has been reported to have an inhibitory effect on human 5-HT3A 
receptors expressed in Xenopus oocytes that was dose dependent and reversible (Choi et al., 2003). 
Using the same model, similar effects have been reported for two ginsenoside metabolites (Lee et al., 
2004). These studies suggest that the reported effects of ginseng on nausea and vomiting may be via 
antagonism of the 5-HT3A receptor. 
Poria cocos 
Tai et al investigated the effects of a range of triterpenes extracted from Poria in frogs orally 
administered copper sulphate as an emetic. The latency to first emesis was significantly prolonged 
compared to controls by some, but not all, triterpenes. Those showing a significant anti-emetic effect 
had an exo-methylene group at C24 in their side chain (Tai et al., 1995).  
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The effects of three Poria-derived triterpenoids [PA: Pachymic acid; DA: dehydroeburicoic acid; HA: 
3β-hydroxylanosta-7,9(11), 24-trien-21-oic acid] on human 5-HT3A receptors was investigated in 
Xenopus oocytes using a two electrode voltage-clamp technique. Each triterpenoid showed 
concentration dependent, reversible inhibition on 5HT-induced inward current with HA showing the 
highest potency (Lee et al., 2009).  
Atractylodes macrocephala 
The effects of an extract of Atractylodes on restitution of the intestinal mucosa after damage, was 
investigated in a cell migration model using intestinal epithelial (IEC-6) cells treated with 
Atractylodes extract, spermidine (SPD, 5 µmol/L) as the positive control, the polyamine inhibitor 
alpha-difluoromethylornithine (DFMO, 2.5mmol/L) as the negative control, and a no treatment 
control. At doses of 100mg/L and 200mg/L, Atractylodes significantly increased IEC-6 cell migration 
after wounding compared to no treatment and the effect was comparable to that of SPD. The effect of 
Atractylodes was retained when combined with DFMO. Atractylodes exposure increased cellular 
polyamine content and other markers indicating a polyamine dependent mechanism (Song et al., 
2015). In human gastric mucosa epithelium, Atractylodes extract promoted the growth of human 
gastric mucosa cells, DNA synthesis and pepsin secretion, but had no effect on acid secretion (Zhu et 
al., 2003). 
Atractylodes has been reported to enhance gastric emptying and small intestinal motility in mice fed 
Atractylodes extract plus the marker Blue dextran 2000, compared to a saline control (Li et al., 
1996).This prokinetic effect could be blocked by atropine in a study of isolated mouse ileum which 
indicated the effect may be mediated via muscarinic receptors (Ma et al., 1996).In guinea pig colon 
sections, Atractylodes extract was reported to increase smooth muscle contraction (Ding et al., 2005).  
Astragalus membranaceus 
A number of studies have investigated the effect of Astragalus on gastrointestinal motility. In healthy 
dogs, the investigators measured the myoelectric activity in the duodenum and jejunum after 25% 
concentrated solution (1 ml/kg) Astragalus extract was injected into the dog’s empty stomach. The 
duration of each myoelectric cycle, each phase of the cycleand the electrical potential were measured. 
The results showed Astragalus could significantly extend the duration of myoeletric cycles in the 
duodenum and jejunum but the motility enhancing effect was most pronounced in the jejunum (Yang 
et al., 1993). In normal mice, Astragalus significantly enhanced small intestine motility and 
antagonized the inhibitive effects of atropine and the non-selective beta-adrenergic 
agonistisoproterenol. In the stomach, Astragalus also antagonized inhibition of gastric emptying 
induced by atropine (3mg/kg), but did not antagonize the dopamine-serotonin receptor antagonist 
metoclopramide (0.8mg/kg) (Zheng et al., 2003).  
In healthy humans, small intestine transmission time was measured by using a hydrogen breath test to 
determine the peak value of lactose absorption after taking 18 g lactose orally. After taking Astragalus 
for one week, the time to the peak value of lactose absorption was significantly shortened, compared 
to before administration of Astragalus, suggesting increased motility (Qiao et al., 2001).  
Glycyrrhiza (Licorice) 
The effects of aqueous extracts of several TMs, including Glycyrrhiza, Astragalus and Atractylodes, 
were tested in isolated smooth muscle strips taken from different gastric regions of the rat. 
Glycyrrhiza, Astragalus, and Atractylodes increased longitudinal and circular fundic muscle tension; 
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Glycyrrhiza and Atractylodes enhanced longitudinal muscle tension in strips from the gastric body; 
while Glycyrrhiza increased the motility index of pyloric circular muscle (Zheng et al., 1998).  
A study that investigated the effects of isoliquiritigenin (a flavonoid in Glycyrrhiza spp.) on 
gastrointestinal motility in mice fed a charcoal meal, found an inhibitory effect at low doses (0.003, 
0.03 mg/kg) and a prokinetic effect at high doses(3 and 30 mg/kg). Subsequent in-vitro studies 
indicated that the spasmogenic effect involved activation of muscarinic receptors, while the 
spasmolytic effect was associated with blockade of calcium channels (Chen et al., 2009).  
Sato et al investigated the effect of glycycoumarin, a compound from Glycyrrhiza, on 
carbamylcholine (CCh)-induced contraction of mouse jejunum and reported an antispasmodic effect 
related to the inhibition of the phosphodiesterase 3 pathway (Sato et al., 2006). 
Coix  
The effect of de-hulled Coix seed was examined in an indomethacin-induced gastric lesion model in 
rats. Erosion of the gastric mucosa was examined by imaging and by histopathological observation. 
Coix extract was found to produce dose-dependent gastroprotection against indomethacin. This effect 
was at least partially due antioxidant actions of the phenolic acids in Coix (Chung et al 2011). A 
methanol extract of Coix seeds was found to reduce nitric oxide and superoxide production in RAW 
264.7 macrophages (Seo et al 2000).  
Safety of the TM interventions 
The included studies did not report any serious adverse events associated with TMs and the meta-
analyses results did not show increased CINV in any of the studies. Also, when combined with anti-
emetic drugs the TMs did not appear to reduce their effectiveness, rather, the results were suggestive 
of enhanced effect. In an analysis of the effects of TMs on tumour response in CRC, the use of TMs 
was not associated with any reduction in the efficacy of the oxaliplatin-based chemotherapy (Chen et 
al., 2015). The six plants identified by the sensitivity analyses are all in common use in traditional 
medicine (Bensky et al., 2004). 
 
Conclusions 
In nausea and vomiting associated with oxaliplatin based chemotherapy for CRC, the addition of TMs 
appears to significantly reduce incidence based on a meta-analysis of 27 studies. This effect was most 
pronounced in the group of 21 studies that administered the TMs orally. There was low statistical 
heterogeneity in this group, the oxaliplatin regiments and CINV measurements were consistent across 
studies and there was considerable similarity in the TMs used but the lack of blinding in most studies 
may have led to overestimation of the effects on CINV. Further sensitivity analysis of the TMs based 
on their ingredients, identified six plants that were associated with significant reductions in CINV 
without important heterogeneity in the meta-analysis results. Experimental studies of these six plants 
have reported inhibitory effects on nausea and vomiting (or its animal equivalent), regulation of 
gastrointestinal motility, gastro-protective effects, and/or antioxidant actions which may at least 
partially explain the effects identified in the meta-analyses of the clinical trial results.These plants 
warrant further clinical research as additions to chemotherapy regimens in patients whose CINV is not 
sufficiently well-controlled by conventional therapies. 
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Figure legends 
Figure 1. Flow diagram of the search and selection process of RCTs of Oxaliplatin regimens 
combined with traditional medicine (TM) for colorectal cancer (CRC) with incidence of nausea and 
vomiting as an outcome 
CT: clinical trial of TM without randomisation; DU: duplicate publication; MT: multi-cancer CT; RE: review; 
Other: not a controlled trial, not a CT of TM. 
 
Figure 2: Forest plot of the effects of traditional medicine (TM) interventions on CINV incidence in 
colorectal cancer (CRC) treated with oxaliplatin regimens 
 
Figure Supp. 1: Funnel plot of CINV outcomes of 27 studies of TMs for CRC: oral and non-oral 
groups 
RR: risk ratio of CINV 
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Figure 1. Flow diagram of the search and selection process of RCTs of Oxaliplatin 
regimens combined with traditional medicine (TM) for colorectal cancer (CRC) with 
incidence of nausea and vomiting as an outcome 
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Figure 2: Forest plot of the effects of traditional medicine (TM) interventions on CINV incidence 
in colorectal cancer (CRC) treated with oxaliplatin regimens 
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Table 1: Characteristics of randomised controlled trials of traditional medicines (TM) combined with oxaliplatin-based regimens for colorectal cancer (CRC) 
with nausea and vomiting incidence as an outcome 
First 
author 
(year). 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
TM Intervention; dosage & 
duration 
Oxaliplatin regimen; dose, cycles (T/C); 
anti-emetic drug. 
Risk of bias (SG, AC, BPt, 
BOA, IOD, SOR)  
Ding X 
(2010). 
30/30; 18/20; 
64.5/63 (med.) 
Co-Kushen injection; 20 ml, ID, 
day 1-7, 14 day/cycle, for 8 cycles. 
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 
1, LV 200mg /m², ID, day 1-2, 5-FU 
400mg /m², bolus, 600mg /m², ID, 22 
hours, day1-2, 8/8 cycles. 
SG: L, AC: U, BPt: H, BOA 
(obj): L, IOD: L SOR: U. 
Fang M 
(2008)
 
48/45; 30/28; 
59.5 ± 11.3/56.4 
± 10.3 
Javanica oil emulsion injection; 30 
ml, ID, day 1-14 / cycles, for two 
cycles 
FOLFOX 4: 2 cycles (all); anti-emetic 
drug used (unknown) 
SG: L, AC: U, BPt: H, BOA 
(subj): H, IOD: L, SOR: U. 
Hu A 
(2006). 
28/22; 18/14; 
49.3±4.5/48.5±4
.3 
Treatment with 4 different TM 
decoctions according to symptom 
differentiation; one decoction per 
day, for more than 30 days. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 
200mg /m², ID, day 1-2, 5-FU 2400mg 
/m², ID, 46 hours, cycle/21 days, 2/2 
cycles; Granisetron, Metoclopramide. 
SG: U, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Kono T 
(2013). 
27/23; NS; 
67/61 (mean) 
TJ-107 Goshajinkigan aqueous 
extract; or placebo was 
administered orally, tid, before each 
meal (7.5 g/day) for 26 wks 
FOLFOX4, or mFOLFOX6: Ox.85 
mg/m², ID, day 1, LV 200mg /m², ID, 5-
FU 400 mg bolus, follow 2400 mg /m², ID 
for 46 hours, 14 days/cycle, 8/8 cycles or 
more. 
SG: L, AC: L, BPt: L, BOA 
(obj): L, IOD: L, SOR: L. 
Lao G 
(2012). 
30/30; 21/23; 
35.1±20.2/36.7±
20.1. 
Jianpijiedu decoction; one 
decoction per day, 21 days /cycle, 
for two cycles. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 
200mg /m², ID, day 1, 5-FU 500 mg bolus 
day 1, 2400mg /m², ID, 48 hours, day 1-2, 
21 days /cycle, 2/2 cycles; 5-HT3 receptor 
antagonist and dexamethasone. 
SG: L, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Li H 
(2007). 
65/52; 43/36; 
58/59 (med.) 
Aidi injection; 60ml, ID, day 1-10, 
14 days/cycle, for 11wks. 
FOLFOX 4: 5.5/5.5 cycles (mean); 
Granisetron. 
SG: U, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Li Y 
(2007). 
20/18; 22 (all); 
72.2 (med. all) 
Wenshenjianpi decoction; one 
decoction per day, for med. 10-12 
wks. 
FOLFOX 4: 6/5.5 cycles (med.). SG: L, AC: U, BPt: H, BOA 
(obj): L, IOD: H, SOR: U. 
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Lim M 
(2012). 
24/23; 17/14; 
56.89±14.77/55.
37±16.01 
Pianzaihuang capsule; two 
capsules, bid; 14 days/cycle, 8-10 
cycles. 
FOLFOX4; 8-10/8-10 cycles. SG: U, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Liu H 
(2009). 
36/34; 16/18; 
50.2 (mean) 
Kang’ai fangyi pian; one decoction 
per day, 21 days / cycle, for 3 
cycles. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 
200mg /m², ID, day 1-5, 5-FU 300 mg 
/m², ID, day 1-5, 21 days / cycle, 3/3 
cycles.  
SG: L, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Liu J 
(2005). 
43/21; 23/10; 
61.52 ±10.12 
/60.11 ±9.78 
Jianpihuoxue formulae; one 
decoction per day, 30 days/ cycle, 3 
cycles. 
FOLFOX; Ox.150 mg/m², ID, day 1, LV 
200mg /m², ID, day 1-5, 5-FU 500 mg 
/m², ID, day 1-5, 30 days/ cycle, 3/3 
cycles; Ondansetron hydrochloride. 
SG: L, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Liu W 
(2011). 
16/16; 11/10; 
51/52(mean) 
Yi er kang capsule; 4-6 capsules, 
bid, for 5-25 months. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 
100mg /m², ID, day 1-5, 5-FU 400 mg 
/m², ID, day 1-5, 21 days / cycle, 6 /6 
cycles; Ondansetron. 
SG: U, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Ma J 
(2005). 
28/25; 15/13; 
58.1/57.5(mean) 
Jianpixiaoliu decoction; one 
decoction per day, 90 days/ cycle, 2 
cycles. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 
200mg /m², ID, day 1-5, 5-FU 375 mg 
/m², ID, day 1-5, 21 days / cycle, 6/6 
cycles. 
SG: U, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Qiu Z 
(2011). 
22/21; 14/13; 
56.9/52.7(med.) 
Kang’ai injection; 40 ml, ID, day 
1–10, 14 days/ cycle, for 4 cycles. 
FOLFOX4, 4/4 cycles. SG: U, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Song W 
(2012). 
20/20; 12/13; 
56.4±9.1 
/48.3±8.2 
Xiaoliuhuajichangfang II; one 
decoction per day, 21 days/ cycle, 2 
cycles. 
FOLFOX: Ox.135 mg/m², ID, day 1, LV 
200mg /m², ID, day 1-2, 5-FU 2400 mg 
/m², ID, for 48 hours, 21 days/ cycle, 2 /2 
cycles; Ramosetron, Metoclopramide.  
SG: L, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Tao C 
(2013). 
74/74; 51/50; 
60.1+7.9 
/60.4+8.9. 
Co-kushen injection; 15 ml per day, 
ID, started 14 days before 
chemotherapy, 5wks/cycle, for 1 
cycle. 
FOLFOX: Ox.135 mg/m², ID, day 1, LV 
200mg/m², ID, 2 hours, day 1-5, 5-FU 
500mg/m² ,ID, 8-10 hours, day1-5, 
3wks/cycle, 1/1 cycle. 
SG: U, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Wang H 
(2008). 
34/34; 20/22; 
52.58±8.12/51.1
1±7.72 
Yiqiguoxiebuchang decoction; one 
decoction per day, for 3 mths.  
FOLFOX: Ox.85 mg/m², ID, day 1, LV 
200mg/m², ID, day 1-2, 5-FU 500 mg 
bolus day 1, 5-FU 2500 mg/m², ID, for 48 
hours, 21 days/ cycle, 4/4 cycles; 
Ondansetron hydrochloride.  
SG: U, AC: U, BPt: H BOA 
(obj): L, IOD: L, SOR: U. 
Wang J 30/30; 18/21; Yichangning decoction; one FOLFOX4, 21 days /cycle, 2/2 cycles; SG: L, AC: U, BPt: H, BOA 
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(2011). 52.3±6.2/ 
56.7±7.8. 
decoction per day, for 2 mths. Ondansetron.  (obj): L, IOD: L, SOR: U. 
Wu G 
(2010). 
33/25; 23/17; 
55.4 ±13.6 /52.8 
±15.2. 
Fupiyiwei decoction; one decoction 
per day, for 24 wks. 
 
FOLFOX 4: 12/12 cycles; Ondansetron 
hydrochloride 
SG: L, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Xu Y 
(2010) 
61/60; 38/37; 
53/52(mean) 
Jiangniling formulae; one decoction 
per day, 14 days/cycle, for 8-10 
cycles 
FOLFOX 4: 11.1/7.8 (mean) cycles; 
Granisetron. 
SG: U, AC: U, BPt: H, BOA 
(subj): H, IOD: L, SOR: U. 
Yang Y 
(2008). 
30/30; 16/19; 
51.07+10.44 
/51.33+10.95. 
Kang'ai injection; 50 ml, ID, day1-
20, 30days/cycle, for 2 cycles. 
FOLFOX4, 4/4 cycles; Granisetron. SG: U, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Yang Z 
(2005)
 
30/30; 18/20; 
29- 70 /28- 69 
Xuesaitong injection, 500 mg,ID; 
Huangqi injection,60 ml,ID; 
Shenmai injection, 50 ml, ID &TM 
decoction, one decoction per day, 
day1-5, 21 days/ cycle, for 2 cycles. 
FOLFOX: Ox.200 mg/m², ID, day 1, LV 
200mg /m², ID, day 1-5, 5-FU 500 mg 
/m², ID day 1-5, 2/2 cycles. 
SG: U, AC: U, BPt: H, BOA 
(subj): H, IOD: L, SOR: U. 
Zhang H 
(2008) 
31/29; 28/23; 
52.35/53.4(mea
n) 
3 TM decoctions based on 
symptom differentiation; one 
decoction per day. Started one 
week before chemotherapy till one 
week after chemotherapy 
completed.  
FOLFOX 4: 4/4 cycles; Ondansetron 
hydrochloride. 
SG: U, AC: U, BPt: H, BOA 
(subj): H, IOD: L, SOR: U. 
Zhang Q 
(2006). 
38/30; 35(all); 
54.8(mean all). 
Yiqihuoxue formulae; one 
decoction per day, 21 days/ cycle, 
for 3 cycles. 
FOLFOX: Ox.125 mg/m², ID, day 1, LV 
200mg /m², ID, day 1-2, 5-FU 500 mg /m² 
bolus, day 1-2, 2000 mg /m² ID for 72 
hours, 21 days/cycle, 3/3 cycles; 
Ondansetron hydrochloride 
SG: L, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Zhang Q 
(2010). 
60/60; 35/33; 
56.2 (mean all);  
Gubenxiaoliu capsule; 4 capsules, 
bid, for 8 wks.  
FOLFOX4, 4/4 cycles; Ondansetron 
hydrochloride. 
SG: L, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Zhang W 
(2013). 
32/32; 15/16; 
56.8±10.1/46.4±
9.2. 
Xiaoliuhuaji Decoction I; one 
decoction per day, for 5 mths.  
FOLFOX: Ox.135 mg/m², ID, day 1, LV 
200mg /m², ID, day 1-2, 5-FU 2400 mg 
/m² , ID for 48 hours, 21 days/cycle, 6/6 
cycles; Ramosetron.  
SG: L, AC: U, BPt: H, BOA 
(obj): L, IOD: L, SOR: U. 
Zhang Y 
(2010). 
21/20; NS; NS;  Jianpijiedu decoction; one 
decoction per day, for 4 wks. 
FOLFOX 4: 2/2 cycles. SG: U, AC: U, BPt: H, BOA 
(obj): L, IOD: H, SOR: U. 
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Zou B 
(2007) 
32/27; 29/22; 
53/54.3(mean)  
Gubenkang'ai decoction; one 
decoction per day, for 6 wks. 
FOLFOX: Ox.135 mg/m², ID, day 1, LV 
200mg /m², ID, day 1-2, 5-FU 2400 mg 
/m², ID, for 48 hours, day 1, 21 days/ 
cycle, for 2 cycles(all); Granisetron, 
Metoclopramide. 
SG: U, AC: U, BPt: H, BOA 
(subj): H, IOD: L, SOR: U. 
T: treatment group, C: control group, M: male, N: number, NS: not stated, ID: intravenous drip, TM: Traditional medicine. 5-FU: 5-Fluorouracil; LV: Leucovorin; 
Ox.: Oxaliplatin; FOLFOX: Ox. + 5-FU + LV; bid: twice per day; tid: three times per day; qd: once per day; Wk: week; Mth: month; med.: median. 
Risk of Bias Categories: SG: Sequence Generation, AC: Allocation Concealment, BPt: Blinding of Participants/Personnel, BOA (obj): Blinding of Outcome 
Assessment (subjective outcome measure i.e. nausea), IOD: Incomplete Outcome Data, SOR: Selective Outcome Reporting. Risk of Bias Judgements: L: low risk, U: 
Unclear risk, H: High risk 
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Table 2: Effects of specific TMs on CINV: Level 1 single TMs 
Traditional Medicine (species) N studies N 
participants 
RR [95% CI] I
2
 
Hordeum vulgare L. (mai ya) 2 98 0.47 [0.33, 0.68] 0 
Crataegus pinnatifida Bge (shan zha) 2 98 0.47 [0.33, 0.68] 0 
Massa medica fermentata (shen qu) 2 120 0.47 [0.30, 0.73] 0 
Panax ginseng C. A. Mey. (ren shen)* 4 222 0.51 [0.39, 0.66] 0 
Glycyrrhiza uralensis Fisch (gan cao)* 3 170 0.51 [0.38, 0.70] 0 
Magnolia officinalis Rehd. et Wils (hou po) 3 179 0.54 [0.38, 0.77] 0 
Amomum kravanh Pierre ex. Gagnep. (bai dou kou) 2 117 0.54 [0.36, 0.81] 0 
Dioscorea opposita Thunb. (shan yao) 5 321 0.56 [0.47, 0.67] 0 
Sophora flavescens Ait. (ku shen) 2 92 0.56 [0.35, 0.92] 0 
Lycium barbarum L. (gou qi zi) 3 168 0.58 [0.41, 0.83] 0 
Cornus officinalis Sieb. et Zucc. (shan zhu yu) 2 139 0.59 [0.46, 0.75] 0 
Paeonia suffruticosa Andr. (mu dan pi) 2 139 0.59 [0.46, 0.75] 0 
Alisma orientalis (Sam.) Juzep. (ze xie) 2 139 0.59 [0.46, 0.75] 0 
Rehmannia glutinosa Libosch. (shu di huang) 3 199 0.60 [0.47, 0.75] 0 
Nelumbo nucifera Gaertn. (lian zi) 2 110 0.60 [0.41, 0.88] 0 
Poria cocos (Schw) Wolf (fu ling)* 16 1012 0.61 [0.54, 0.69] 15 
Coix lacryma-jobi L. (yi ren)* 14 945 0.61 [0.53, 0.70] 29 
Codonopsis pilosula (Franch.). Nannf. (dang shen) 12 747 0.61 [0.52, 0.72] 28 
Paeonia lactiflora Pall. (bai shao) 5 272 0.61 [0.48, 0.76] 0 
Panax notoginseng (Burk.) F.H. Chen (tian qi) 4 245 0.61 [0.43, 0.87] 0 
Atractylodes macrocephala Koidz. (bai zhu)* 16 976 0.62 [0.54, 0.71] 13 
Eclipta prostrata L. (mo han lian) 2 129 0.63 [0.41, 0.97] 0 
Sophora japonica L. (huai hua) 3 150 0.63 [0.46, 0.86] 0 
Scutellaria barbata D. Don. (ban zhi lian) 6 356 0.64 [0.50, 0.81] 0 
Page 22 of 23
http://mc.manuscriptcentral.com/ptr
Phytotherapy Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Astragalus membranaceus (Fisch.) Bge. (huang qi)* 13 733 0.65 [0.55, 0.76] 0 
Ligusticum chuanxiong Hort. (chuan xiong) 2 114 0.65 [0.46, 0.92] 0 
Angelica sinensis (Oliv.) Diels. (dang gui) 2 118 0.68 [0.50, 0.92] 11 
Hedyotis diffusa Willd. (she she cao) 4 228 0.69 [0.51, 0.93] 0 
Akebia quinata (Thunb.) Decne. (ba yue zha) 5 264 0.70 [0.51, 0.95] 0 
Curcuma zedoaria (Berg.) Rosc. or C. phaeocaulis 
Val. (e zhu) 
7 439 0.71 [0.57, 0.88] 0 
Spatholobus suberectus Dunn (ji xue teng) 3 192 0.73 [0.55, 0.98] 0 
*Included in the final six TMs. 
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